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Abstract. Drug repositioning refers to the identification of new therapeutic indications for
drugs already approved. Albendazole and ricobendazole have been used as anti-parasitic
drugs for many years; their therapeutic action is based on the inhibition of microtubule
formation. Therefore, the study of their properties as antitumor compounds and the design of
an appropriate formulation for cancer therapy is an interesting issue to investigate. The
selected compounds are poorly soluble in water, and consequently, they have low and erratic
bioavailability. In order to improve their biopharmaceutics properties, several formulations
employing cyclodextrin inclusion complexes were developed. To carefully evaluate the
in vitro and in vivo antitumor activity of these drugs and their complexes, several studies were
performed on a breast cancer cell line (4T1) and BALB/c mice. In vitro studies showed that
albendazole presented improved antitumor activity compared with ricobendazole. Further-
more, albendazole:citrate-β-cyclodextrin complex decreased significantly 4T1 cell growth
both in in vitro and in vivo experiments. Thus, new formulations for anti-parasitic drugs could
help to reposition them for new therapeutic indications, offering safer and more effective
treatments by using a well-known drug.
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INTRODUCTION
Cancer is a major cause of mortality worldwide despite
of the large number of treatment and prevention studies.
According to the World Health Organization estimates, by
2030, the global incidence is expected to increase to 21.7
million cancer cases [1–3]. Currently, chemotherapy is one
of the most effective strategies to avoid the proliferation of
malignant tumors [3, 4]. However, the ability of cancer cells
to become resistant to different drugs remains a significant
impediment to successful chemotherapy [1]. In this sense,
drug repositioning has emerged as an alternative strategy
for cancer treatment. Drug repositioning refers to the
identification of new therapeutic indications for drugs
already approved [5, 6]. There are innumerable advantages
as well as challenges for drug repositioning. For instance,
drug repositioning is an alternative strategy to accelerate
drug discovery, since the discovery of new active pharma-
ceutical ingredients takes a lot of effort and economic
impact [7–9]. Moreover, repositioned drugs are relatively
inexpensive and carry minimal risk due to the availability of
previous pharmacological, safety, and toxicology data,
significantly decreasing the costs for treatments with asso-
ciated low toxicity [10–14]. Drug repositioning, as a new
strategy, benefits patients by offering safer and effective
treatments using well-known drugs [15, 16].
Albendazole (ABZ) and ricobendazole (RBZ) are
benzimidazole derivatives usually employed as antihelmintic
compounds [17, 18]. The pharmacological activities of these
drugs are focused in the inhibition of tubulin polymerization
and blockage of glucose uptake. Thus, these compounds
produce depletion of glycogen stores and decrease the
adenosine triphosphate (ATP) formation in the larval and
adult stages of parasites [19–21]. Microtubule formation is
involved in cell division; therefore, its inhibition is currently
one of the goals of medicinal chemistry in cancer chemother-
apy [22].
Research on ABZ antitumor activity has been carried
out on ovarian cancer cell lines [23, 24], and other studies
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were performed on HCT-116 (a colorectal cancer cell line) in
which ABZ was formulated as hydroxypropyl-β-cyclodextrin
(HP-β-CD) inclusion complexes [25, 26].
Castro et al. (2016) reported an interesting study on
MCF7 breast cancer cells, showing that ABZ promotes
oxidative DNA damage, which induces DNA fragmentation,
apoptosis, and cell death [1]. In addition, Sorlie et al. (2003)
described the effect of ABZ on MCF7, an estrogen receptor-
positive cell line, extending the putative use of ABZ for the
treatment of triple-negative breast tumors, the type of breast
cancer with worse associated prognosis and limited therapeu-
tic options [27, 28].
Despite their therapeutic efficacy, both ABZ and RBZ
present poor aqueous solubility and limited absorption after
oral administration. Pharmaceutical technology has devel-
oped several strategies to overcome solubility and absorption
limitations of insoluble drugs such as solid dispersions [29],
micellar formulations [30, 31], nano- and microstructured
systems [20, 32, 33], co-crystals [34], and cyclodextrin (CD)
inclusion complexes [35–39].
CDs are cyclic oligosaccharides, formed by glucopyra-
nose units linked by covalent bonds α-1,4 forming a torus-like
macroring shape, having an inner cavity with hydrophobic
affinity and an outer surface with hydrophilic affinity [40, 41].
The locations of hydrophobic molecules inside the CD cavity
usually produce significant improvement in many attributes,
such as solubility, bioavailability, and stability [42].
β-CD has reached pharmaceutical relevance despite its
low aqueous solubility, since chemical modifications increase
this parameter due to the loss of the crystalline solid state.
Furthermore, Lajos Szente and Jozsef Szejtli [43] postulated
that the random substitution of any hydroxyl group produces
an interference of the stable hydrogen bond system around
the β-CD rims causing an enhancement of the aqueous
solubility. Thus, many CDs have been synthesized to enhance
the physicochemical properties of poorly soluble drugs, such
as methyl-β-CD, HP-β-CD, sulfobutyl ether-β-CD, succinyl-
β-CD, and citrate-β-CD [35–37, 39, 42, 44, 45]. Several
techniques have been proposed for the preparation of CD
inclusion complexes, which can be grouped into three
categories: methods in solid state, methods in semi-solid
state, or methods in solution. This latest involves removing
the solvent from solutions of drug and CD by coevaporation/
coprecipitation, spray-drying, or colyophilization [46]. Spray-
drying involves feeding an aqueous solution into an atomizer
that produces small droplets which are exposed to relatively
high air temperatures in a short time [47]. In the present
work, the spray-drying technique was selected because it
strongly influences the properties of the obtained material
such as size, morphology, and shape that generally increase
dissolution rate [48]. Thus, the use of CDs as pharmaceutical
excipients is an excellent practice to improve the physico-
chemical and pharmaceutical properties of poorly soluble
drugs [42].
Therefore, the goal of this work was to prepare ABZ and
RBZ-CD inclusion complexes by spray-drying procedure to
study their putative use for triple-negative breast cancer
treatment. These promising CD formulations could help to
reposition ABZ and RBZ for new therapeutic indications
offering safer and effective treatments employing well-known
drugs.
MATERIALS AND METHODS
Materials
ABZ was obtained from Parafarm (Buenos Aires,
Argentina). RBZ was kindly donated by Laboratorio Proagro
SA (Rosario, Argentina). β-CD was donated by Roquette. S-
β-CD and C-β-CD were synthesized in our laboratory as
described previously [36, 37]. 4T1 cells were kindly provided
by Dr. N. Zwirner (IBYME-CONICET), RPMI 1640 was
purchased from Gibco (Waltham, Massachusetts, USA), and
WST-1 (2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium) reagent was from Sigma-
Aldrich (St. Louis, MO, USA). All other chemicals were of
analytical grade.
Methods
Phase Solubility Diagrams
The stoichiometry and equilibrium constants for complex
formation were determined by phase-solubility studies. Water
solutions of β-CD and their derivatives were prepared using
increasing concentrations from 0 to 50 mM. After that, an
excess amount of each active pharmaceutical ingredient
(API) was added. These solutions were kept in sealed vials,
under stirring at 180 rpm for 72 h at room temperature.
Solutions were filtered through a 0.45-μm cellulose nitrate
filter and ABZ and RBZ concentrations were determined in
a Boeco S-26 spectrophotometer at 294 and 284 nm, respec-
tively. The inclusion complex formation constants (Kf) were
calculated by Eq. 1:
Kf ¼ SS0 1−Sð Þ ð1Þ
where S0 is the API intrinsic solubility and S is the slope
obtained by plotting the phase-solubility diagrams (37).
Preparation of Physical Mixtures and Inclusion Complexes
The complexes were prepared in 1:1 M ratio. Briefly,
ABZ and RBZ were solubilized in glacial acetic acid. On the
other hand, CDs were solubilized in bidistilled water. Drug
and CD solutions were mixed under stirring and immediately
dried in a Büchi Mini Spray Dryer B-290. The studies were
performed under the following conditions: temperature
130°C, pump efficiency 15% (flow rate 5 mL/min), and
aspirator set 100%. The solid product obtained was kept in
an oven at 40°C for 24 h. In addition, physical mixtures were
prepared in a mortar for comparison.
Apparent Solubility
The apparent solubility of ABZ and RBZ in the CD
inclusion complexes and physical mixtures were determined
adding an excess amount of complex (corresponding to 10 mg
of API) in vials with 5 mL of bidistilled water, in an orbital
shaker at 180 rpm for 72 h. Afterward, the solutions were
filtered and the concentration of APIs was determined by UV
spectroscopy.
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Characterization of the Physical Mixtures and the Inclusion
Complexes
Fourier-Transform Infrared Spectroscopy. Fourier-trans-
form infrared spectra were obtained by an FT-IR-Prestige-21
Shimadzu (Tokyo, Japan) using the KBr disk method (2 mg
sample in 100 mg KBr). Scanning range was 450 to 3900 cm−1
with a resolution of 1 cm−1.
Differential Scanning Calorimetry. Differential scanning
calorimetry (DSC) was performed on a Shimadzu TA-60
(Kyoto, Japan) calorimeter, using 5-mg samples in crimped
aluminum pans. The instrument was calibrated with indium
and zinc as standards. Nitrogen was used as a purge gas, and
an empty aluminum pan was employed as a reference. Each
sample was scanned at a rate of 5°C/min from 25 to 350°C,
under N2 atmosphere (flow rate 30 mL/min).
X-ray Diffraction. Data collection was carried out in
transmission mode on an automated X’Pert Philips MPD
diffractometer (Eindhoven, Netherlands). X-ray diffraction
patterns were recorded using CuKα radiation (λ = 1.540562 Å),
40 kV voltage, 20 mA current, and steps of 0.02° on the interval
2θ = 10°–40°. Low peak broadening and background were
assured by using parallel beam geometry with an X-ray lens
and a graphite monochromator placed before the detector
window. Data acquisition and evaluation were performed with
the Stoe Visual-Xpow package, Version 2.75 (Germany).
NMR Experiments. Two-dimensional rotating-frame
Overhauser effect spectroscopy (ROESY) experiments were
carried to confirm complexation ofABZandRBZwith the studied
β-CDs, as well as to characterize their binding mode. The RBZ:C-
β-CD complex (10 mg) was solubilized in 0.5 mL 0.1 N DCl in
D2O. ROESY measurements were performed with a Bruker
Avance 300 instrument (Karlsruhe, Germany) with a 5-mm probe
using the roesyph pulse sequence (Bruker) with the experimental
conditions as follows: 32 scans, acquisition time 0.295 s, pulse delay
1.92 s, and 512 data points. Resonance at 4.7 ppm was used as an
internal reference due to residual solvent water.
Dissolution Studies. Dissolution studies were performed
in 900 mL 0.1 N HCl at 37°C, according to the US
Pharmacopeia [49] by using an Apparatus 2 (SR8 8-Flask
Bath, Hanson Research, Chatsworth, CA) with paddle
rotating at 50 rpm. Samples of ABZ and RBZ pure drug,
physical mixtures, or spray-dried complexes equivalent to
100 mg of the drug were spread on the surface of the
dissolution medium and the time 0 was recorded. At
appropriate time intervals, 5-mL samples were withdrawn
and filtered (pore size 0.45 mm). The amount of drug released
was determined by UV analysis, measuring the absorbance
spectrophotometrically at 291 nm (ABZ) and 289 nm (RBZ).
In Vitro Studies
Drug Content Determination. Drug content determina-
tion has been done as follows: an accurately weighed quantity
of the inclusion complexes (10.0 mg) was dissolved in 100 mL
0.1 N HCl. Drug concentration was measured spectrophoto-
metrically. The obtained value was 15.9 ± 0.5% w/w.
Doses of ABZ:C-β-CD inclusion complex were calcu-
lated according to the ABZ content and corresponded to
30 mg of ABZ per kilogram of body weight.
Stock Solutions. Stock solutions were prepared in
DMSO (37.7 mM ABZ and 35.5 mM RBZ and their inclusion
complexes with C-β-CD), then were diluted in phosphate-
buffered saline (pH 7.4) and finally in complete RPMI 1640
medium until reaching the desired concentration. The final
concentration of DMSO did not exceed 0.1%.
Cell Proliferation Assay. Cell proliferation assay was
carried out to determine the effect of the benzimidazole
compounds on proliferative activity of 4T1 cell line. Briefly,
2 × 103 cells/well were seeded in 96-well plates and cultured in
RPMI 1640 medium, which was supplemented with 10% fetal
bovine serum and 1% antibiotic (penicillin 10 U/mL +
streptomycin 10 μg/mL), at 37 °C in a 5% CO2 atmosphere
for 8 h to allow cell attachment. Then, the medium was
replaced by free-drug or complex-drug solution.
After 48 h of incubation, WST-1 reagent was added and
the absorbance was read on a Rayto RT-2100C microplate
reader (Shenzhen, P. R. China).
Half maximal inhibitory concentration (IC50) values
were obtained from the absorbance curves as function of
the API concentration by using GraphPad Prism 7
(GraphPad Software, La Jolla, CA, USA).
In Vivo Studies
Six to 8-week-old BALB/c mice were obtained from
ICiVet-Litoral (Esperanza, Santa Fe, Argentina). All exper-
iments were performed in accordance with the Canadian
Council on Animal Care guidelines [50]. Animals were fed
with commercial chow and water ad libitum and maintained
in a 12-h light/dark cycle.
In order to assess primary breast cancer cell growth, 5 ×
104 4T1 cells were resuspended in PBS and injected (100 μL)
orthotopically into the right mammary gland of the recipient
mouse. When tumors reached ~ 150 mm3, animals (n = 5–8/
group) were randomly distributed in three groups as follows:
control (no treatment), ABZ, and ABZ:C-β-CD complex.
Table I. Values of Equilibrium Constants of the Complexes (Kf,
M−1). R2 Values Obtained from the Linear Fit Are Indicated in
Parentheses [37]
ABZ RBZ
β-CD 74 (0.722) 212 (0.998)
Me-β-CD 337 (0.995) 197 (0.999)
HP-β-CD 313 (0.996) 177 (0.999)
S-β-CD 515 (0.995) 124 (0.984)
C-β-CD 1037 (0.998) 287 (0.993)
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These last two groups were treated with 30-mg ABZ/kg oral
doses, three times weekly for 53 days. Tumor growth was
analyzed by measuring tumor length (a) and width (b) with a
caliper, and by calculating tumor volume (V) with Eq. 2 [51]:
V ¼ 0:4ab2 ð2Þ
Data were fit to an exponential growth curve and a two-
tailed Student’s t test was performed in GraphPad Prism
software 7 (GraphPad Software, La Jolla, CA, USA).
When tumors reached the largest ethically permitted
volume, animals were euthanized and their lungs excised and
fixed, and the number and size of metastatic foci determined
macroscopically. Absence of symptoms of toxicity in the
animals was verified on a daily basis.
RESULTS AND DISCUSSION
Characterization of the Physical Mixtures and Inclusion
Complexes
Fourier-transform infrared spectroscopy, differential
scanning calorimetry, and X-ray diffraction studies have been
done to analyze the solid state of ABZ and RBZ in physical
mixtures and in the CD inclusion complexes (data not
shown).
Those results suggest that ABZ and RBZ are in an
amorphous state after the complex formation process [37, 52].
Phase Solubility Diagrams
CDs could enhance apparent water solubility by forming
dynamic, water-soluble inclusion complexes [42]. This inter-
action is an equilibrium governed by an equilibrium constant,
Kf. AL-type profiles (linear relationship) were obtained by
plotting ABZ or RBZ concentration and increasing concen-
tration of CDs. A-type profiles represent the formation of
water-soluble CD complexes in 1:1 M ratio [42].
Kf calculated values are shown in Table I and Fig. 1
shows the A-type profiles.
ABZ and RBZ presented the highest Kf values using C-
β-CD as an excipient. Solubility improvement could be
attributed to the stabilization of the complex by electrostatic
interactions between the positive charge of the API and the
negative charge of the C-β-CD.
Fig. 1. Phase solubility diagram. Concentration of ABZ and RBZ against increasing
concentrations of CDs
Fig. 2. ROESY spectrum. a RBZ proton labelling. b C-β-CD proton labelling. c Plot of two-dimensional ROESY spectrum
of RBZ in the presence of C-β-CD
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Differences in Kf values between both APIs in the
presence of C-β-CD may be due to a lower hydrophobicity
of RBZ in comparison with ABZ due to the presence of the
sulfoxide group in the molecule of RBZ.
NMR Experiments
The characterization of the CD derivative and the
inclusion complex is extremely important to understand the
host-guest molecule interaction. Different NMR spectroscopy
analyses (1H-13C heteronuclear single-quantum correlation,
HSQC, heteronuclear multiple bond correlation, HMBC, and
rotating-frame overhauser effect spectroscopy, ROESY) were
used to study the structural characteristics of supramolecular
aggregates. ROESY NMR experiment provides information
for investigating inter- and intra-molecular interactions and it
is relevant in order to determine the possible inclusion mode
of complexes. In this technique, the observation of ROESY
cross-peaks indicates that the distance between the involved
hydrogen nuclei is below 0.4 nm.
ROESY spectrum of the system ABZ:C-β-CD was
previously described (Garcia et al. 2014) [37].
The proton labels of RBZ and C-β-CD and the partial
ROESY spectrum of the system RBZ:C-β-CD are shown in
Fig. 2. In this figure, cross-peaks between the internal C-β-
CD protons and Be^ (δ = 7.57 ppm), Bf^ (δ = 7.68 ppm), and
Bg^ (δ = 7.80 ppm) protons that pertain to aromatic ring of
RBZ could be observed. In addition, intermolecular cross-
peaks were observed between the Ba^ (δ = 0.85 ppm) and Bb^
(δ = 1.50 ppm) protons and the internal protons of C-β-CD.
These results indicated that the non-polar portion of the guest
structure could be included in the cavity of C-β-CD. Similar
interactions were observed for ABZ:C-β-CD, as it was
described in Garcia et al. (2013).
Apparent Solubility and Dissolution Profiles
Tables II and III show the apparent solubility and drug
release values of API formulations (inclusion complexes and
physical mixtures). As might be expected, solubility and
dissolution rate increased in the presence of CDs observing
better results for inclusion complexes than physical mixtures.
The most important increase in solubility was observed
employing the C-β-CD inclusion complexes. ABZ solubility
increased 615 times compared to the ABZ as a pure drug,
while RBZ, 112 times. Apparent solubility values for the C-β-
CD complexes are according to the Kf values.
Drug release results showed a clear improvement in the
dissolution rate of the CD inclusion complexes, suggesting a
benefit for potential oral dosage forms.
Effect of ABZ and RBZ and Their Cyclodextrin Inclusion
Complexes on Cell Proliferation and Their Cyclodextrin
Inclusion Complexes on Cell Proliferation
Both benzimidazole compounds presented anti-
proliferative activity on 4T1 cell line. The decrease in cell
growth was dose dependent, but a saturation effect was
reached as shown in Fig. 3. While ABZ concentrations higher
Table II. Apparent Solubility Values of Complexes and Physical
Mixtures. The Values Are Expressed as Mean (mg/mL) ± Standard
Deviation [37]
ABZ RBZ
API 0.0013 ± 0.0007 0.06 ± 0.02
β-CD complex 0.024 ± 0.001 2.331 ± 0.004
β-CD physical mixture 0.013 ± 0.002 0.28 ± 0.01
Me-β-CD complex 0.069 ± 0.002 4.3 ± 0.1
Me-β-CD physical mixture 0.016 ± 0.001 0.9 ± 0.4
HP-β-CD complex 0.048 ± 0.001 3.2 ± 0.4
HP-β-CD physical mixture 0.011 ± 0.004 1.00 ± 0.05
S-β-CD complex 0.143 ± 0.003 4.7 ± 0.7
S-β-CD physical mixture 0.016 ± 0.002 1.11 ± 0.05
C-β-CD complex 0.799 ± 0.009 6.7 ± 0.7
C-β-CD physical mixture 0.172 ± 0.004 1.9 ± 0.1
Table III. In Vitro Dissolution Data of Inclusion Complexes and Physical Mixtures. Drug Released (%) at 10, 30, and 60 min (Q10, Q30, and
Q60) ± Standard Deviation
Sample ABZ RBZ
Q10 (%) Q30 (%) Q60 (%) Q10 (%) Q30 (%)
API 2.0 ± 1.0 3.8 ± 2.1 6.1 ± 2.9 68.5 ± 0.4 100.5 ± 0.7
β-CD complex 23.7 ± 2.2 34.5 ± 1.9 46.6 ± 1.4 102.8 ± 0.5 –
β-CD physical mixture 3.2 ± 0.6 7.7 ± 0.1 12.6 ± 0.2 99.6 ± 1.1 –
Me-β-CD complex 101.1 ± 2.2 99.0 ± 2.1 94.8 ± 1.3 101.6 ± 3.3 –
Me-β-CD physical mixture 53.2 ± 0.7 62.9 ± 1.1 68.3 ± 1.4 104.2 ± 2.7 –
HP-β-CD complex 39.8 ± 2.3 54.8 ± 2.0 65.6 ± 1.2 103.1 ± 2.1 –
HP-β-CD physical mixture 13.0 ± 1.9 22.5 ± 0.9 31.3 ± 1.1 102.5 ± 1.2 –
S-β-CD complex 77.1 ± 2.5 91.8 ± 0.4 95.5 ± 1.9 103.0 ± 3.4 –
S-β-CD physical mixture 10.7 ± 2.4 25.2 ± 2.2 44.3 ± 3.2 100.5 ± 2.3 –
C-β-CD complex 92.7 ± 2.2 97.5 ± 2.1 96.8 ± 1.3 98.5 ± 0.3 –
C-β-CD physical mixture 34.3 ± 2.4 49.0 ± 2.2 57.0 ± 3.2 104.0 ± 0.4 –
– Totally dissolved
Repositioning of Anti-parasitic Drugs
Author's personal copy
than 0.5 μM significantly decreased cell growth, higher
concentrations of RBZ were required to achieve the same
effect. For this reason, we decided to focus our studies on the
antitumor effect of ABZ.
A recent study in a breast cancer model (MCF-7 cells)
showed that ABZ inhibited cell viability [1]. Nevertheless, it
is worthwhile to note that we obtained the same results in a
more aggressive model. Among breast cancer subtypes,
triple-negative breast cancer exhibits distinct characteristics,
is particularly aggressive and frequently recurrent, and
becomes metastatic [3]. These subtypes of tumors account
for 15% of all breast cancer types with higher percentages in
premenopausal African-American and Hispanic women, and
it is associated with very poor prognosis and limited
treatment option availability [51]. As shown in Fig. 4, the
ABZ:C-β-CD complex decreased significantly 4T1 cell
growth when compared to the untreated control. Noteworthy,
differences were not statistically significant between cells
exposed to CDs and control cells.
The IC50 value obtained for ABZ was 0.56 ± 0.02 μM
while for the ABZ:C-β-CD complex was 0.41 ± 0.30 μM.
Although ABZ:C-β-CD complex showed lower values of
IC50 than ABZ, no statistically significant differences were
observed.
In Vivo Studies
The effect of treatment with ABZ and ABZ:C-β-CD
complex on 4T1 cells in BALB/c mice was analyzed (Fig. 5).
Mice treated with the ABZ:C-β-CD complex developed
tumors which showed significantly slower growth kinetics
compared with the other groups. After 53 days of inoculation,
significant differences in tumor volume were observed
between complex and the other treatments (p < 0.01). These
results show the potentiality of the ABZ complex to reduce
significantly the volume of tumors. The examination of
animals, at the end of the assay, indicated no differences in
the number of lung metastasis (data not shown).
Fig. 3. Cells were cultured in the presence of increasing doses of ABZ or RBZ during
48 h. The number of metabolically active cells was estimated by tetrazolium salts reduction
method (n = 3; *p < 0.05, **p < 0.01)
Fig. 4. Cells were cultured in the presence of the ABZ, C-β-CD, and
ABZ:C-β-CD complex (0.5 μM) during 48 h. The number of
metabolically active cells was estimated by tetrazolium salts reduction
method (n = 3; **p < 0.01, ***p < 0.001)
Fig. 5. Immunocompetent mice were orthotopically challenged with
4T1 cells. Tumor size was measured biweekly with a caliper
(**p < 0.01)
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CONCLUSIONS
Inclusion complexes of ABZ and RBZ were prepared
with β-CD and its derivatives. The apparent solubility of the
APIs was highest when C-β-CD derivative was used as
carrier. This increase in solubility was higher for ABZ,
indicating the formation of a more stable complex than with
RBZ. Additionally, ABZ showed in vitro anti-proliferative
activity at lower doses than RBZ on 4T1 cell line. Further-
more, in vivo studies showed that ABZ:C-β-CD complex
allowed reducing the tumor growth kinetics on BALB/c mice
with no signs of toxicity. These findings can lead to an
effective therapy against triple-negative breast cancer by
combining of ABZ:C-β-CD complex with other antitumor
drugs.
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